RESULTS OF ADVANCED IMMUNOLOGICAL STUDIES IN COMPREHENSIVE SURGICAL TREATMENT OF BRONCHIECTASIS

Abstract

The prevalence of bronchiectasis (BE) is not clearly defined in the literature. Weiker et al. reported that 340,000 to 522,000 adults in the United States were treated for bronchiectasis, and 70,000 adults were newly diagnosed with bronchiectasis in 2013 [6]. Another study shows that there were more than two million adult patients with bronchiectasis worldwide in 2012, and this number is expected to exceed three million by 2020 [2, 4].
Since bronchiectasis is characterized by inflammation of the lungs, anti-inflammatory drugs may theoretically be useful. However, a systematic review of the effectiveness of nonsteroidal anti-inflammatory drugs and corticosteroids in the treatment of bronchiectasis showed no clear benefit [1, 5].
From an immunological point of view, bronchiectasis is of great interest because it allows us to understand the mechanisms of immunodeficiency and the subsequent persistent inflammatory response to bacterial infection. It also provides an opportunity to manipulate the immune response to improve patient outcomes. It should be noted that there are many different factors that can contribute to the development of bronchiectasis (after infections , immunodeficiency , dysfunction of the mucous membrane, systemic inflammatory diseases, airway obstruction), and their pathogenesis is not fully understood [3] .